MegaPro Biomedical Co News
News
0
Ticker
6827.TWO
ISIN
TW0006827009
Actualités Eulerpool MegaPro Biomedical Co
Actualités de l'action MegaPro Biomedical Co
MegaPro Biomedical Co est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant MegaPro Biomedical Co.
Communiqués de presse relatifs à l'action MegaPro Biomedical Co
MegaPro Biomedical Co publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.
MegaPro Biomedical Co News 2026
Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action MegaPro Biomedical Co (6827.TWO, ISIN : TW0006827009). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez MegaPro Biomedical Co.
MegaPro Biomedical Co Action
MegaPro Biomedical Co MegaPro Biomedical Co., Ltd. generates revenue through its development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's primary products are MPB-1514, MPB-1523, MPB-1734, and MPB-2043, each targeting specific medical conditions. MPB-1514 treats anemia in chronic kidney disease patients via intravenous injection, while MPB-1523 diagnoses hepatocellular carcinoma through intravenous administration. MPB-1734 addresses solid tumors with intravenous treatment, and MPB-2043 aids in diagnosing metastases in peripheral lymph nodes of cancer sites. These products are sold to healthcare providers and medical institutions requiring advanced diagnostic and therapeutic solutions. The company focuses on two core technology platforms: nanoparticle and nanocell, which underpin its product development. Its product portfolio targets chronic kidney disease, hepatocellular carcinoma, solid tumors, and cancer metastasis diagnostics. These applications are directed toward medical professionals and facilities specializing in oncology and nephrology. The firm's revenue model relies on the commercialization of these specialized drug ingredients for targeted medical treatments and diagnostics. MegaPro Biomedical's products are designed for intravenous use across various medical conditions, positioning the company within the biotechnology sector. Its revenue streams come from the sale of these proprietary drug ingredients to hospitals, clinics, and research institutions. The company's market segments include healthcare providers treating kidney disease, cancer diagnostics, and oncology-focused medical facilities seeking innovative therapeutic solutions.